Biomarin Pharmaceutical Inc. (BMRN)
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin (BMRN) Upgraded to Buy: Here's Why
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMRN vs. INCY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Brian Mueller - Executive Vice President and Chief Financial Officer Cristin Hubbard - Executive Vice President and Chief Commercial Officer Greg Friberg - Executive Vice President and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Salveen Richter - Goldman Sachs Jessica Fye - JPMorgan Paul Matteis - Stifel Eli Merle - UBS Cory Kasimov - Evercore Kostas Biliouris - BMO Capital Markets Joseph Schwartz - Leerink Partners Akash Tewari - Jefferies Christopher Raymond - Piper Sandler Mohit Bansal - Wells Fargo John Wang - Barclays Operator Thank you for standing by. My name is Bailey and I will be your conference operator today.
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago.
